Adam Samson

Outline clinical evidence needed for regulatory bodies and public and private health insurers across nine countries across North America, Europe, and the Asia-Pacific region to adopt DTx. Establish best practices for clinical trial design and execution for digital therapeutics (with input from DTA members) that would generate the evidence required for specific regulatory bodies and payors.

Part of a group comprised of 31 team members, representing a variety of stakeholders, tasked with updating CTTI’s recommendations and deliverables related to decentralized clinical trials.

Core Team Member for DTRA Initiative 2B Mapping the Patient Journey. This initiative falls under DTRA Priority 2: Standardize Best Practices.

• Identified, defined, categorized, and refined components of DCTs (and their intersection with components of traditional trials)
• Wrote site guidance questions for consideration
• Outlined process, budget, and regulatory implications
• Developed guidance tool to support sites’ budgeting process and empower sites to ask and rationalize requests for compensation related to services in support of study implementation and management
• Conducted a comprehensive review of federal… Show more

• Identified, defined, categorized, and refined components of DCTs (and their intersection with components of traditional trials)
• Wrote site guidance questions for consideration
• Outlined process, budget, and regulatory implications
• Developed guidance tool to support sites’ budgeting process and empower sites to ask and rationalize requests for compensation related to services in support of study implementation and management
• Conducted a comprehensive review of federal research conduct guidelines and suggested modifications to ease adoption of DCTs and to promote “standards of excellence” in the implementation of DCTs at the site level Show less

Support CISCRP’s mission of educating and informing the public and patients about clinical research by reviewing communications and providing feedback on items such as usability, clarity, and design.

I’m fortunate to be a participant in Pfizer’s COVID-19 vaccine trial. My experience has been overwhelmingly positive, and it has allowed me to gain first-hand insights into the experience of clinical trial participants. To do my small part in helping improve the clinical trial journey for participants, I am doing my best to apply this knowledge every day to the studies I design and lead. Given that I have already received so much, both personally and professionally, from my participation, I… Show more

I’m fortunate to be a participant in Pfizer’s COVID-19 vaccine trial. My experience has been overwhelmingly positive, and it has allowed me to gain first-hand insights into the experience of clinical trial participants. To do my small part in helping improve the clinical trial journey for participants, I am doing my best to apply this knowledge every day to the studies I design and lead. Given that I have already received so much, both personally and professionally, from my participation, I made the voluntary decision to donate the compensation that I'm receiving for my participation to the Center for Information and Study on Clinical Research Participation (CISCRP). Show less